Increasing microbial resistance is creating a demand for new drugs, which is currently not matched by privately-funded research and development, making it all the more important to obtain protection with smart, cost effective IP strategies for novel inventions addressing the innovation void.
The repurposing of drugs can also be protected by patents, which requires experience and expertise in second-medical use claims to provide the best possible support.
Universities and research institutions, start-up companies and SMEs all benefit from the wide-ranging, commercially relevant experience of HGF’s anti-infectives IP team, who possess deep knowledge and understanding of the shifting patent laws that affect innovators in areas relating to anti-infective agents.
HGF’s specialist attorneys combine extensive legal, scientific and transactional expertise with in-house backgrounds to develop multijurisdictional IP protection strategies across antibiotics, antivirals, immunomodulators and vaccines, as well as diagnostic methods and technologies.
The anti-infectives team specialises in patent and trade mark protection, with targeted and industry-validated advice on drafting and prosecuting, including second medical use type claims and cross jurisdictional drafting of patent applications. Furthermore, the attorneys are highly accomplished across oppositions and appeals in biologics, small molecule drugs and diagnostic devices, freedom-to-operate analysis, in-and-out licensing and supplementary protection certificates (SPCs).
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
How to streamline the trade mark selection process by conducting effective, in-house ‘dirty searches’. Selecting the right trade mark for your new healthcare product is a critically important task. Consumers …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
World Intellectual Property Day is on 26th April. This year’s theme is IP & SME’s: Taking your ideas to market. World IP day 2021 shines a light on the critical role of …Event details
‘IP & data protection for alternative proteins: how to protect your products in the EU’ webinar will be held on Tuesday 18th May. Join this webinar by BGP, HGF & …Event details